Texas is currently home to 4857 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Modern Research Associates, Dallas, Texas
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT06013241
Recruiting
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: USA025, Dallas, Texas
Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
NCT06012136
Recruiting
The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single and multiple ascending SC and IM doses of capsid inhibitors in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: HIV Infections
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Austin, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
04/17/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Single Ventricle Heart Disease
Register for Updates
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579
Recruiting
The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for adva... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
NCT05866679
Recruiting
To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.
Gender:
FEMALE
Ages:
18 months and above
Trial Updated:
04/17/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
Register for Updates
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
04/17/2025
Locations: The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Conditions: Muscular Atrophy, Spinal
Register for Updates
Genetic Disorders of Obesity Program Database
NCT05747976
Recruiting
This study collects data on children with severe, early-onset obesity.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Obesity, Childhood, Genetic Disease
Register for Updates
Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT05744557
Recruiting
To learn if applying vapocoolant anesthetic spray ("Nüm") on the surface of the intended injection site will reduce the pain/anxiety associated with breast injections.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Dermatology Treatment and Research Center, Dallas, Texas
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634
Recruiting
To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates